Study 7 of 7Cagrilintide (AM833) literaturebiorxiv-preprint · Meta-analysis2025
Cagrilintide–Semaglutide Combination Therapy Versus Monotherapy or Placebo: A Systematic Review and Meta-Analysis
The abstract is not available, preventing any conclusions about the study's findings or implications.
Where it sits
this study against the rest of the cagrilintide (am833) corpus2
Preclinical
1
Observational
0
Open-label
0
Randomised
4
Reviews · this one
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2025
Background
The study appears to address the efficacy of combination therapy with Cagrilintide and Semaglutide compared to monotherapy or placebo. This is relevant as both peptides have been investigated for weight management and metabolic disorders, but their combined effect is less understood.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Without access to the abstract or full text, it is impossible to determine how the findings compare to existing literature or their clinical significance. The lack of detailed information limits any interpretation.
Key findings
- Not reported in abstract.
Limitations
- Abstract not available
- Preprint status
- Unknown sample size
- Unknown study design
- Unknown outcome measures
Elsewhere in the Cagrilintide (AM833) corpus
AOnce-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?europepmc · 2022 · n=1961 · –14.9% weight loss vs placebo at 68 wk, n=1961, p<0.001reviewAEfficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.europepmc · 2024 · n=1500 · MD -9.07% weight loss at 20-32 weeks with Cagrisema vs semaglutide, 95%CI: -11.91, -6.23; p < 0.00001; I2 = 96%reviewDClinical studies on anti-obesity medications in Arab countries.europepmc · 2025 · 32.2% of patients reported gastrointestinal side effects.reviewDSemaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.europepmc · 2025 · Not reported in abstract.reviewDNovel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.europepmc · 2026 · -17.18% body weight change with high dose CagriSema vs placeboreviewCAM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists.PubMed · 2021 · Cagrilintide (AM833) had an EC50 value of 0.5 nM for receptor activation.review